Acupuncture and Related Therapies for the Cognitive Function of Alzheimer’s Disease: A Network Meta-Analysis

Xue-Song Wang 1,2, Jia-Jia Li 3, Yue-Shen Wang 4, Chao-Chao Yu 5,6, Chuan He 1,2, Zhong-Sheng Huang 1,2, Tao Jiang 1,2, *Qing Hao 1,2, *Li-Hong Kong 1,2

1. College of Acupuncture and Orthopedics, Hubei University of Chinese Medicine, Wuhan, Hubei, China
2. Hubei Provincial Collaborative Innovation Center of Preventive Treatment by Acupuncture and Moxibustion, Hubei University of Chinese Medicine, Wuhan, Hubei, China
3. Hubei Rongjun Hospital, Wuhan, Hubei, China
4. Xuzhou Cancer Hospital, Xuzhou, Jiangsu, China
5. Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangzhou, China
6. The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, Guangzhou, China

*Corresponding Author: Email: 525080422@qq.com; xiyu1618@sina.com

(Received 14 Feb 2021; accepted 06 Apr 2021)

Abstract
Background: Acupuncture and acupuncture-related therapies are effective for Alzheimer’s disease (AD), therefore, we aimed to compare and rank the interventions that mainly focus on acupuncture-related therapies in the treatment of patients with mild to moderate AD.

Methods: We used network meta-analysis to evaluate the direct and indirect evidence shown in randomized controlled trials of AD. The data were analyzed using RavaMan manager, Stata, and WinBUGS software after two researchers independently screened the literature, extracted the data, and assessed the risk of bias in the included studies.

Results: We analyzed a total of 36 eligible studies, including 2712 patients, involving 14 types of acupuncture-related therapies and comprehensive therapies. For Mini-Mental State Examination (MMSE), acupuncture (ACU) combined with cognitive and memory training (Training) was more effective than ACU, ACU+Chinese herb (CH), ACU+Donepezil (DON), CH, DON, DON+Nimodipine (NIM), Music therapy (Music), NIM, Placebo, and Training (P<0.05), while ACU+CH was better than CH (P<0.05), and ACU+DON+NIM was better than DON+NIM (P<0.05). For Alzheimer’s Disease Assessment Scale-Cognitive section (ADAS-cog), ACU was more effective than DON and placebo (P<0.05). For Activities of Daily Living (ADL), ACU+DON was better than CH, DON, NIM, and Placebo (P<0.05). For the clinical effectiveness rate, ACU, ACU+CH, ACU+CH+DON, ACU+CH+DON+NIM, ACU+DON, CH, NIM were all more effective than DON+NIM (P<0.05), while ACU and ACU+CH were better than DON (P<0.05). The comprehensive ranking results show that ACU+training and ACU have the highest ranking probability.

Conclusion: ACU+Training and ACU may be the best therapies to improve the cognitive function of patients with mild to moderate AD, while the combination of acupuncture-related therapies and other therapies has a higher overall benefit.

Keywords: Acupuncture; Alzheimer's disease; Cognitive function; Network meta-analysis

Available at: http://ijph.tums.ac.ir
Introduction

Alzheimer's disease (AD), mainly characterized by progressive memory and cognitive decline, can have a great effect on patients' daily living ability. According to the latest report from the Alzheimer's Association, the number of patients with AD has increased year by year, and nearly one million new cases will be added each year by 2050 (1). Notably, it has been more than a hundred years since AD was first discovered, however, it remains one of the world's biggest challenges (2).

AD accounts for 80% of all types of dementia and is one of the main threats to the health of older people. Age is the most relevant risk factor besides genetic factors, with most sporadic AD patients' onset after the age of 65 (3). Gender is another important risk factor for the onset of AD. The meta-analysis shows that the prevalence of dementia is 19% to 29% higher in females than in males (3). In addition, vascular factors (such as cardiovascular disease, hypertension, hyperlipidemia, etc.) and unhealthy lifestyles are also important factors affecting the development of AD. And because of that, AD has become one of the most important medical and social problems in the world under the trend of global aging (4, 5). Currently, cholinesterase inhibitors are preferred as clinical drug therapies to alleviate symptoms, although they carry a high rate of adverse reactions (6-8). Although the National Medical Drugs Administration of China has conditionally approved the marketing of the mild to moderate AD drug Oligomannate (GV-971), the existing evidence does not fully demonstrate the pharmacological mechanism, long-term safety and efficacy of GV-971, and further experimental and clinical research evidence is still needed to support the feasibility of its clinical promotion (9).

In China, acupuncture has a long history of use in the treatment of brain diseases, and there is abundant evidence that acupuncture has satisfactory efficacy in the treatment of vascular dementia, Parkinson's disease, depression, and other diseases. In recent years, a series of basic and clinical studies have shown the potential of acupuncture in the treatment of AD. Results from recent systematic reviews and meta-analysis have shown that acupuncture may effectively improve the cognitive function of patients with AD (10-13). However, due to the wide variety of acupuncture therapies, we still lack comparative studies between the different acupuncture therapies. In this study, we used a network meta-analysis to compare the efficacy of various therapies compared with acupuncture-related therapies for AD, in order to provide evidence-based medical evidence for selecting the best choice to improve the cognitive function in patients with mild to moderate AD.

Methods

This study was conducted following the preferred reporting items for systematic reviews and meta-analyses for network meta-analysis (PRISMA-NMA) checklist (14). The PRISMA-NMA checklist has revised 11 NMA-related items based on the 27 items in the PRISMA checklist and added 5 new items to guide and improve the writing and reporting of NMA (15).

Literature Retrieval

Our literature search was performed from database establishment until Feb 25, 2021, using the following databases: PubMed, Embase, the Cochrane Library, the Web of Science, the China Biology Medicine (CBM), the China National Knowledge Infrastructure (CNKI), Wanfang Data, and the Chinese Scientific Journal Database (VIP). The search was conducted using a combination of medical subject headings (MeSH) terms and free words.

Inclusion Criteria

For our analysis, we screened published clinical randomized controlled trial (RCT) involving acupuncture-related therapies for AD patients regardless of age or gender, clearly diagnosed with
mild to moderate AD by specific clinical guidelines (i.e., the American Psychiatric Association Diagnostic and Statistical Manual for Mental Disorders (DSM-IV-R)) (16), as well as the diagnostic criteria formulated by the Alzheimer’s Association and National Institute on Aging (NIA-AA) (17) and operational criteria for the diagnosis of AD (OCDAD) (18), among other relevant clinical guidelines. Interventions include pharmacological therapies such as donepezil (DON), nimodipine (NIM), and Chinese Herbs (CH), or non-pharmacological therapies such as acupuncture and acupuncture-related therapies (ACU), music therapy (Music), cognitive or memory rehabilitation training (Training), or the combination of the above therapies. At least one of the following outcome indicators was included: Primary Outcome: Mini-Mental State Examination (MMSE) and Alzheimer’s Disease Assessment Scale-Cognitive section (ADAS-cog), Secondary Outcome: Activities of Daily Living (ADL) and Effectiveness Rate.

Exclusion Criteria
In our analysis, we excluded: ① Non-randomized controlled trials; ② No clear diagnostic criteria and/or efficacy evaluation criteria; ③ Other types of dementia, such as vascular dementia; ④ Without sufficient and/or clear original data; or ⑤ Repeated studies and/or studies reporting the same results.

Two researchers, ZH and TJ, independently conducted the literature screen, data extraction, and cross-check. In any case of disagreement, they would discuss to reach a consensus or a third researcher, CY would assist in the final determination. A unified table was used for data extraction, which included: ① basic information (e.g., first author’s name, publication year, among others); ② the baseline characteristics from each intervention group (e.g., sample size, age); ③ intervention parameters (e.g., types of acupuncture, frequency, duration of treatment); and ④ outcome indicators.

Our two researchers, JL and YW, evaluated the included studies following the bias risk assessment tool recommended on Cochrane Handbook 5.1 (19). Including seven parts: random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and other bias.

Statistical Analysis
STATA (ver. 15.0), RevMan manager (ver. 5.3), and WinBUGS (ver. 1.4.3) software were used in our statistical analysis (20, 21). The effectiveness rate was categorically variable, risk ratio (RR) with 95% confidence intervals (CI) was used. However, the MMSE, ADAS-cog, and ADL scores were numerical variables, standard mean difference (SMD) with 95% CI was used. The differences between baseline and after treatment were used as the effect size. If there were some data were not reported in some trials, we used the following formula to estimate the missing data (22):

\[
\bar{X}_{\text{change}} = \bar{X}_{\text{post-treatment}} - \bar{X}_{\text{baseline}}
\]

\[
\text{SD}_{\text{change}} = \sqrt{\left(\text{SD}_{\text{baseline}}\right)^2 + \left(\text{SD}_{\text{post-treatment}}\right)^2 - 2 \times \text{r} \times \text{SD}_{\text{baseline}} \times \text{SD}_{\text{post-treatment}}}
\]

Firstly, the standard pairwise meta-analysis was performed using the RevMan manager. We calculated the I-square (I²) test to assess heterogeneity among RCTs (23). If I² > 50%, they were analyzed using random-effects model; otherwise, fixed-effect model was chosen.

Second, we used the STATA to make NMA evidence diagram (24). We used the WinBugs to analyze the data, when running the WinBugs program, four chains were used for simulation, the number of iterations was set to 100,000 times, the first 10,000 times were used for annealing to eliminate the influence of the initial value. Inconsistency factors (IF) with 95% CI were used to evaluate the consistency of each closed-loops. For closed-loops, if the IF with 95% CI contains 0, it indicates that the direct and indirect evidence were very consistent (25).
Third, we could judge whether there were small sample effects in this study by plotting the funnel plot (26).
Finally, the surface under the cumulative ranking curve (SUCRA) was generated using the STATA software to show the SUCRA scores, which means the probability of each intervention being ranked best, with a higher SUCRA score indicating a higher treatment level (27, 28).

**Results**

**Study Search and Description**

Overall, 8,045 related studies were retrieved from the databases, after deleting 3,149 duplicate studies, removing 4,815 studies by reading the title, abstract, and the full text, 36 studies were included in the final analysis. Our analysis included three four-arm trials (29-31), one three-arm trial (32), and the remainder were two-arm trials. All the studies were from the USA (33), Japan (34), Hong Kong (35), Taiwan (36), and China mainland, involving 14 interventions: acupuncture and acupuncture-related therapies (ACU), Chinese Herbs (CH), donepezil (DON), nimodipine (NIM), music therapy (Music), cognitive or memory rehabilitation training (Training), placebo, and the combination of the above therapies, ACU+CH, ACU+CH+DON+NIM, ACU+DON, ACU+DON+NIM, ACU+Music, and ACU+Training. The basic characteristics of the included studies are shown in Table 1, while the results of the literature screening are shown in Fig. 1.

**Table 1: Basic characteristics of the included studies**

| Studies (year) | country  | Intervention          | Treatment | n  | Years (mean±sd)/range | Control | n  | Years (mean±sd)/range | course | outcomes |
|---------------|----------|-----------------------|-----------|----|-----------------------|---------|----|-----------------------|--------|----------|
| Zhu et al. (29) | China    | CH                    | 20        |    | 72.3±6                | DON     | 20 | 72.3±6                | 8w     | 1        |
|               |          | ACU                   | 20        |    | 72.3±6                |         |    |                       |        |          |
|               |          | ACU+CH                | 20        |    | 68±9                  | DON     | 20 | 69±7                  | 12w    | 1        |
| Feng et al. (37) | China    | ACU                   | 20        |    | 72.3±6                |         |    |                       |        |          |
| Yan et al. (38) | China    | ACU                   | 20        |    | 60-78                 | DON     | 20 | 60-80                 | 12w    | 1        |
| Li et al. (30) | China    | ACU+CH                | 35        |    | 67±4                  | NIM     | 14 | 65±7                  | 8w     | 1③④     |
|               |          | ACU                   | 37        |    | 65±6                  |         |    |                       |        |          |
|               |          | CH                    | 18        |    | 66±4                  |         |    |                       |        |          |
| Peng et al. (32) | China    | ACU+CH                | 28        |    | 62-79                 | DON     | 28 | 60-78                 | 12w    | 1③④     |
|               |          | CH                    | 28        |    | 61-78                 |         |    |                       |        |          |
|               |          | ACU                   | 72        |    | 75±7                  | DON     | 69 | 72±7                  | 16w    | 1②③     |
| Gu et al. (39) | USA      | DON                   | 13        |    | 72.1±8.0              | Placebo | 13 | 72.7±8.0              | 24w    | 2        |
| Mu et al. (40) | Vietnam  | ACU+CH                | 21        |    | 66.1±5.3              | ACU     | 21 | 65.3±4.5              | 8w     | 1③④     |
| Zhu et al. (41) | China    | ACU                   | 30        |    | 62.13±7.99            | NIM     | 30 | 60.90±7.52            | 8w     | 1        |
| Salloway et al. (33) | USA | DON                   | 13        |    | 72.1±8.0              | Placebo | 13 | 72.7±8.0              | 24w    | 2        |
| Doi et al. (34) | Japan    | Music                 | 67        |    | 76.2±4.6              | placebo | 67 | 76.0 ±4.9             | 40w    | 1        |

Available at: [http://ijph.tums.ac.ir](http://ijph.tums.ac.ir)
| Study                      | Location                  | Intervention                        | N  | Effect 1 | Duration | Notes |
|---------------------------|----------------------------|-------------------------------------|----|----------|----------|-------|
| Li et al. (36)            | Taiwan, China             | Music                               | 21 | 76.7±8.45| 6m       | ①    |
| Grace et al. (35)         | Hong Kong, China          | Training                            | 7  | 77.7±6.07| 3m       | ①    |
| Ou et al. (42)            | China                     | ACU                                 | 16 | 65.53±6.8 | 8w       | ③    |
| Jia Y et al. (43)         | China                     | ACU                                 | 43 | 75.11±6.53| 12w      | ②, ③ |
| Cheng et al. (44)         | China                     | ACU+CH+DON+NIM                       | 30 | 64.7±3.7 | 3m       | ①, ③, ④ |
| Li et al. (45)            | China                     | ACU+Training                        | 40 | 68.43±7.56| 3m       | ①, ③, ④ |
| Tang et al. (46)          | China                     | ACU+CH                              | 50 | 58.81    | 12w      | ①, ④ |
| Wang et al. (47)          | China                     | ACU+CH+DON                          | 45 | 68.89±3.22| 24w      | ③, ④ |
| Yao et al. (48)           | China                     | ACU+CH                              | 24 | 76.52±6.365| 60d     | ①, ④ |
| Wang et al. (49)          | China                     | ACU                                 | 36 | 72.05±3.70| 12w      | ①, ③, ④ |
| Yang et al. (50)          | China                     | ACU+CH                              | 36 | 80.5±7.8 | 8w       | ①, ③, ④ |
| Jiang et al. (31)         | China                     | CH                                  | 20 | 60-80    | 12w      | ①, ③ |
| Liu et al. (51)           | China                     | ACU                                 | 35 | 69.1±4.4 | 8w       | ①, ②, ③ |
| Jia Z et al. (52)         | China                     | ACU                                 | 35 | 75.11±6.53| 12w      | ①, ②, ③ |
| Lin et al. (53)           | China                     | ACU                                 | 18 | 73.44±3.37| 12w      | ①, ②, ③ |
| Zhao et al. (54)          | China                     | ACU                                 | 16 | 67±2.12  | 2m       | ①, ③, ④ |
| Dai et al. (55)           | China                     | ACU+Training                        | 47 | 71.06±5.45| NR       | ①, ③, ④ |
| Liu et al. (56)           | China                     | ACU+Music                           | 20 | 71.25±10.93| 120d    | ①, ③ |
| Zhou et al. (57)          | China                     | ACU                                 | 13 | 71.6±8.1 | 6m       | ①, ②, ③ |
| Sun et al. (58)           | China                     | ACU                                 | 55 | 66.23±4.12| 6m       | ①    |
| Chen et al. (59)          | China                     | ACU+DON                             | 48 | 74.36±5.47| 3m       | ①, ③, ④ |
| Bi et al. (60)            | China                     | ACU                                 | 37 | 71.5±4.7 | 12w      | ①, ④ |
| Wang et al. (61)          | China                     | ACU+DON                             | 28 | 70.3±8.0 | 20d      | ①, ② |
Zhao et al. China ACU+Music 60 72.0±10.9 placebo 60 5.71±0.86 4w ①③④
Xia et al. China ACU+DON 30 49±11 DON 30 50±12 8w ①③④
Wang et al. (64)

ACU: acupuncture and related Therapies; CH: Chinese herb; DON: donepezil; NIM: nimodipine; Training: memory and cognitive function training; y: year; m: month; d: day; ①: MMSE; ②: ADAS-cog; ③: ADL; ④: effectiveness rate.

Fig. 1: Study flow diagram

Available at: http://ijph.tums.ac.ir
Quality Assessment of Included Studies

Our two researchers, ZH and TJ, evaluated the included studies according to the bias risk assessment tool recommended by the Cochrane Handbook 5.1. However, acupuncture, music therapy, and memory and cognitive training were non-pharmacological therapies, so some participants and researchers involved in these studies were unable to be blinded. The results of risk evaluation are shown in Fig. 2.

![Quality assessment of included studies](image)

Among the 36 trials, 36 trials (100%) represented a random sequence generation process. Ten trials (27.78%) described the use of allocation concealment methods, and eight trials (22.22%) described the blinding methods for participants or outcome assessment. 35 trials (97.22%) reported complete outcome data. Because of the particularity of the acupuncture operation, it is impossible to be blinded to the participants and personnel.

Results of Pairwise Meta-Analyses

Primary Outcome: MMSE and ADAS-cog

For the results of MMSE, ACU was more efficacious than the following interventions: DON (SMD:0.532, 95%CI:0.148,0.917), NIM (SMD:0.780, 95%CI:0.062,1.498), placebo (SMD:3.814, 95%CI:0.020,7.608). Acupuncture combined therapies were more efficacious than monotherapy, such as ACU+Training (SMD:6.979, 95%CI:4.569,9.389) was more efficacious than Training, ACU+DON (SMD:2.837, 95%CI:1.031,4.643) was more efficacious than DON, ACU+CH (SMD:1.577, 95%CI:1.181,1.974) was more efficacious than ACU, and ACU+CH (SMD:1.501, 95%CI:0.834,2.169) was more efficacious than CH. Regarding the ADAS-cog, ACU (SMD:-3.135, 95%CI:-3.95,-2.32) was more efficacious than DON.

Secondary Outcome: ADL and Effectiveness Rate

For the result of ADL, ACU was more efficacious than the following interventions: DON (SMD:-0.976, 95%CI:-1.844,-0.109), NIM (SMD:0.780, 95%CI:0.431,1.129). ACU+CH was more efficacious than the following interventions: ACU (SMD:-2.399, 95%CI:-2.858,-1.940),
DON (SMD:-0.439, 95%CI:-0.656,-0.223), CH (SMD:-0.374, 95%CI:-0.599,-0.150). Regarding the effectiveness rate, ACU+CH (RR:4.214, 95%CI:1.399,12.690) was more efficacious than DON.

**NMA Results**

As shown in Fig. 3A, 32 studies reported MMSE, involving 14 interventions. After the consistency test, the result included 9 closed-loops, whose IF with 95% CI of 7 closed-loops contained 0, indicating no obvious inconsistencies, whereas the IF with 95% CI of another 2 closed-loops failed to contain 0 (Fig. 4A).

The results of the NMA showed that ACU+Training was more efficacious than the following interventions: ACU (SMD:-7.22; 95%CI:-13.55,-0.67), ACU+CH (SMD:-7.22; 95%CI:-13.55,-0.67), ACU+DON (SMD:-8.72; 95%CI:-15.54,-1.69), CH (SMD:8.97; 95%CI:2.48,15.36), DON (SMD:9.30; 95%CI:2.87,15.57), DON+NIM (SMD:8.44; 95%CI:0.95,15.84), Music (SMD:11.22; 95%CI:5.15,17.25), NIM (SMD:8.70; 95%CI:1.78,15.20), Placebo (SMD:11.72; 95%CI:6.29,17.24), and Training (SMD:7.05; 95%CI:3.65,10.44). In addition, ACU+CH (SMD:1.77; 95%CI:0.09,3.49) was more efficacious than CH, ACU+DON+NIM (SMD:4.09; 95%CI:0.15,7.95) was more efficacious than DON+NIM, and ACU+Training (SMD:7.05; 95%CI:3.65,10.44) was more efficacious than Training, all of them indicated that acupuncture combined with other therapies could improve the
efficacy. The best therapy to improve MMSE was ACU + Training (86.6%), while the worst was Placebo (2.9%) (Fig. 5A). As shown in Fig. 3B, 9 studies reported ADAS-cog, involving 6 interventions. The results of inconsistency test showed that there was 1 closed-loop that did not include 0 (Fig. 4B). The results of the NMA showed that ACU was more efficacious than DON (SMD: -3.45; 95% CI: -6.00, -1.38) and Placebo (SMD: -5.09; 95% CI: -9.34, -1.86). The most effective intervention for reducing the ADAS-cog was ACU (77.8%), while the worst was placebo (1.1%) (Fig. 5B). Therefore, ACU may be the best therapy for patients with mild to moderate AD to improve their cognitive function.

Fig. 4: Inconsistency test chart.
Secondary Outcome: ADL and Effectiveness Rate

As shown in Fig. 3C, 22 studies reported ADL, including 14 interventions. After the consistency test, the result included 9 closed-loops, whose IF with 95% CI of 5 closed loops contained 0, indicating no obvious inconsistencies, whereas the IF with 95% CI of another 4 closed loops failed to contain 0 (Fig. 4C). The results of the NMA showed that ACU+DON was more efficacious than the following interventions: CH (SMD: -5.93; 95%CI: 11.05, -2.05), DON (SMD: -5.29; 95%CI: 9.33, -1.87), NIM (SMD: -5.60; 95%CI: -11.32, -1.66), Placebo (SMD: -7.13; 95%CI: -20.03, 5.78). The most effective intervention for improving the activity ability was ACU+Music (84.4%), while the worst was ACU+DON (8.7%) (Fig. 5C).

As shown in Fig. 3D, 18 studies reported the effectiveness rate, including 13 interventions. After the consistency test, the result included 8 closed-loops, whose IF with 95% CI contained 0, indicating no obvious inconsistencies (Fig. 4D). The following interventions were more efficacious than DON+NIM: ACU (RR: 10.33; 95%CI: 1.74, 244.24), ACU+CH (RR: 22.61; 95%CI: 3.84, 485.73), ACU+CH+DON (RR: 13.98; 95%CI: 1.57, 445.27), ACU+CH+DON+NIM (RR: 4.60; 95%CI: 1.11, 20.40), ACU+DON (RR: 12.97; 95%CI: 1.38, 222.50), CH (RR: 8.49; 95%CI: 1.11, 190.80), NIM (RR: 0.11; 95%CI: 0.00, 0.79). ACU (RR: 2.24; 95%CI: 1.24, 4.23) and ACU+CH (RR: 4.71; 95%CI: 2.32, 11.27) were more efficacious than DON. The most effective intervention for the
effectiveness rate was ACU+CH (93.2%), while the worst was DON+NIM (4.4%) (Fig. 5D). All studies were symmetrically distributed around the X=0 vertical line, and the funnel plot was symmetrical, indicating that there was no evidence of small sample effects in the study network (Fig. 6).

**Adverse Events**

Of the 33 trials included, 9 trials reported adverse events occurred. Six trials reported adverse events related to gastrointestinal discomforts, such as diarrhea, nausea, vomiting, these interventions were mainly DON, CH, and NIM. Five trials reported dizziness, insomnia as adverse effects mainly related to DON. And 3 trials reported bleeding and ecchymosis at the acupuncture site as adverse events.

**Discussion**

AD is a neurodegenerative disease that currently has no specific drugs that can stop its deterioration (65). In recent years, TCM has been widely used in the treatment of AD (66, 67). Moreover, according to a previous meta-analysis, acupuncture-related therapies (10, 68) appear to be more advantageous than western medicine. In other words, acupuncture methods can be beneficial as complementary and alternative therapies for AD.

Our NMA consisted of 33 RCTs, which included 2,469 patients with mild to moderate AD. For these patients, there were three main findings in this NMA: ①ACU+Training may be the optimal therapy to improve MMSE scores; ②ACU may be most helpful in improving ADAS-cog scores and ADL scores; ③the combination of acupuncture-related therapies and other therapies has a higher overall benefit. Although some pharmacological treatments (such as donepezil, etc.) have shown slight efficacy, however, there were still some safety problems that exist. The adverse events reports showed that some participants experienced gastrointestinal reactions and insomnia due to DON, NIM and CH interventions. Overall, the possibility of adverse reactions to pharmacological treatment was higher than that of non-pharmacological treatment.

Compared with the previous meta-analysis (10, 12, 68, 69), the NMA methods were used in our research, we included more interventions for comparison and ranked the different interventions and calculated the probability of the best
intervention. In addition, we included more comprehensive data. Our findings reconfirm the safety and efficacy of acupuncture and acupuncture-related therapies in patients with mild to moderate AD.

In normal brain tissue, the amyloid-beta (Aβ) protein mainly exists in the form of Aβ40, and its generation and elimination are in a dynamic equilibrium state (70). Under physiological conditions, an appropriate amount of soluble Aβ can protect brain cells, while under pathological conditions, Aβ will be overexpressed, causing Aβ deposition and the formation of senile plaques (SP) that are detrimental to brain function (71). Moreover, Aβ can cause excessive phosphorylation of the tau protein (72), which leads to the formation of neurofibrillary tangles (NFTs) (73), and the number of NFTs is positively correlating to the degree of clinical dementia (74, 75). Acupuncture can reduce the levels of Aβ (76) and tau proteins (77), and activate low protein kinase signaling pathways to a certain extent (78), which could restore the learning and memory impairments of AD rats. In addition, acupuncture may have a neuroprotective effect in the AD brain (79, 80) and may also improve neural synaptic plasticity (81-83), activate related brain regions (84), and thus play a role in the prevention and treatment of AD.

Nonetheless, our study has some limitations. The majority of our studies being published in Chinese journals, there may be a publication bias due to Chinese cultural considerations. The risk bias assessment of those included studies was mostly unclear. All the studies analyzed were aimed at short-term efficacy observations, thus the long-term efficacy of acupuncture for AD still needs to be defined.

Conclusion

ACU+Training and ACU can improve MMSE score and cognitive function. Among the interventions we included, ACU+Training and ACU may be the best therapies to improve cognitive function, while the combination of acupuncture-related therapies and other therapies has a higher overall benefit.

Ethical considerations

Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.

Funding

This work was supported by National Natural Science Foundation of China (No.81373741); “Qihuang” Project on Inheritance and Innovation of Traditional Chinese Medicine funded by National Administration of Traditional Chinese Medicine (No.284, 2018); Project on Masters of Chinese Medicine in Hubei province funded by Hubei Provincial Health and Family Planning Commission (No.15, 2018).

PROSPERO registration number CRD42020156183.

Conflicts of interest

All authors declare that they have no potential conflicts of interest.

References

1. Association As (2018). 2018 Alzheimer’s disease facts and figures. *Alzheimer’s & Dementia, 14* (3):367-429.
2. Zhang L, Li Z (2014). Alzheimer and the discovery of Alzheimer’S Disease. *Zhonghua Yi Shi Za Zhi*, 44 (5):288-290.
3. Prince M, Bryce R, Albanese E, et al (2013). The global prevalence of dementia: a systematic review and metaanalysis. *Alzheimers Dement, 9* (1):63-75, e62.
4. Nichols E, Szoeke CE, Vollset SE, et al (2019). Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *The Lancet Neurology*, 18 (1):88-106.
5. Livingston G, Sommerlad A, Orlota V, et al (2017). Dementia prevention, intervention, and care. *Lancet*, 390 (10113):2673-2734.
6. Kuduszkiewicz H, Zimmermann T, Beck-Bornholdt H-P, et al (2005). Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. *BMJ*, 331 (7512):321-327.
7. Lanctôt KL, Herrmann N, Yau KK, et al (2003). Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. *CMAJ*, 169 (6):557-564.
8. Tricco AC, Soobiah C, Berliner S, et al (2013). Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis. *CMAJ*, 185 (16):1393-1401.
9. Wang X, Sun G, Feng T, et al (2019). Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression. *Cell Research*, 29 (10):787-803.
10. Zhou S, Dong L, He Y, et al (2017). Acupuncture plus herbal medicine for Alzheimer's disease: a systematic review and meta-analysis. *Am J Chin Med*, 45(7):1327-1344.
11. Lin L, Li H, Shi H, et al (2017). Acupuncture and moxibustion in the treatment of senile dementia: a meta-analysis. *Chinese Journal of Gerontology*, 37 (20):5014-5016.
12. Zhou J, Peng W, Xu M, et al (2015). The effectiveness and safety of acupuncture for patients with Alzheimer disease: a systematic review and meta-analysis of randomized controlled trials. *Medicine (Baltimore)*, 94 (22):e933.
13. Luan K, Gao W, Sun Q, et al (2019). Clinical Research Progress of AD Treated by Acupuncture and Moxibustion. *Journal of Clinical Acupuncture and Moxibustion*, 35 (5):83-86.
14. Hutton B, Salani G, Caldwell DM, et al (2015). The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann Intern Med*, 162(11):777-784.
15. Fleming PS, Koletsi D, Pandis N (2014). Blinded by PRISMA: are systematic reviewers focusing on PRISMA and ignoring other guidelines? *PLoS One*, 9(5):e96407.
16. Association AP. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR): American Psychiatric Association; 1994.
17. McKhann GM, Knopman DS, Chertkow H, et al (2011). The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. *Alzheimers Dement*, 7(3):263-269.
18. Tian J. Chinese Guidelines for the Diagnosis and Treatment of Alzheimer’s Disease and Other Dementias. Beijing: People’s Medical Publishing House; 2012.
19. Green S (2011). Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration. Available from: https://training.cochrane.org/handbook.
20. Shim S, Yoon B-H, Shin I-S, et al (2017). Network meta-analysis: application and practice using Stata. *Epidemiol Health*, 39:e2017047.
21. Stephenson M, Fleetwood K, Yellowlees A (2015). Alternatives To Winbugs for Network Meta-Analysis. *Value in Health*, 18 (7):A720.
22. Higgins JP, Green S (2008). Cochrane Handbook for Systematic Reviews of Interventions. *Journal of Multidisciplinary Evaluation*, 6:142-148.
23. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. *BMJ*, 327(7414):557-560.
24. Zhang C, Yan J, Sun F, et al (2014). Differentiation and Handling of Homogeneity in Network Meta-analysis. *Chinese Journal of Evidence-Based Medicine*, 14(7):884-888.
25. Liu Y, Zhang M, Li J (2007). Bayesian econometrics based on WinBUGS software. *Journal of East China Institute of Technology (Social Science)*, 26 (2):101-107.
26. Dias S, Sutton AJ, Ades AE, et al (2013). Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. *Med Decis Making*, 33 (5):607-617.
27. Salanti G, Ades A, Ioannidis JP (2011). Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol, 64(2):163-171.

28. Chaimani A, Higgins JP, Mavridis D, et al (2013). Graphical tools for network meta-analysis in STATA. PLoS One, 8(10):e76654.

29. Zhu H, Dong K, Wu Y, et al (2010). Effect of "busibenhuoxue" on cognitive function improvement in patients with Alzheimer's Disease. Chinese Journal of Gerontology, 30 (11):1493-1495.

30. Li Z, Mu Y, Ou Y (2002). Clinic control research of Alzheimer's Disease by the combination of acupuncture and Danggui Shaoyao San (DGSYS) of TCM. Modern Rehabilitation, 6 (19):2848-2849.

31. Jiang W, Tian H, Hu J, et al (2018). Effect of "JinSanZhen" Combined with "JianNaoSan" on Cerebral Blood Flow in Patients with Alzheimer's Disease. Jiangsí Journal of Traditional Chinese Medicine (Chinese), 49 (08):51-53.

32. Peng X, Dong K (2009). Clinical observation on acupuncture combined with Yizhi Jiannao granules for treatment of Alzheimer's disease. Zhongguo Zhen Jiu, 29 (4):269-271.

33. Salloway S, Ferris S, Kluger A, et al (2004). Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology, 63(4):651-657.

34. Doi T, Vergheese J, Makizako H, et al (2017). Effects of Cognitive Leisure Activity on Cognition in Mild Cognitive Impairment: Results of a Randomized Controlled Trial. J Am Med Dir Assoc, 18(8):686-691.

35. Lee GY, Yip CC, Yu EC, et al (2013). Evaluation of a computer-assisted errorless learning-based memory training program for patients with early Alzheimer's disease in Hong Kong: a pilot study. Clin Interv Aging, 8:623-633.

36. Li CH, Liu CK, Yang YH, et al (2015). Adjunct effect of music therapy on cognition in Alzheimer's disease in Taiwan: a pilot study. Neuropsychiatr Dis Treat, 11:291-296.

37. Feng Q, Bin L, Zhai Y, et al (2019). Long-term efficacy and safety of electroacupuncture on improving MMSE in patients with Alzheimer's disease. Zhongguo Zhen Jiu, 39(1):3-8.

38. Yan X, Li Z, Hua Q, et al (2014). The effect of Tousanshen acupuncture in the treatment of Alzheimer's disease on plasma Tau protein. Journal of Bengbu Medical College, 39 (03):302-303+306.

39. Gu W, Jin X, Zhang Y, et al (2014). Clinical observation of Alzheimer's disease treated with acupuncture. Zhongguo Zhen Jiu, 34(12):1156-1160.

40. Mu Y, Li Z (2001). The Treatment of Alzheimer's Disease by the Combination of Acupuncture and Medicine. Shanghai Journal of Acupuncture & Moxibustion, 20 (03):3-5.

41. Zhu C, Cai S, XU B, et al (2015). Clinical Effect of Tongdu Tiaoshen Acupuncture in Treatment of Amnestic Mild Cognitive Impairment. Journal of Anhui University of Chinese Medicine, 34 (03):55-58.

42. Ou Y, Li Z, Mu Y, et al (1999). Clinical study on acupuncture treatment of Alzheimer's disease. Chinese Acupuncture & Moxibustion, 19 (07):15-17+14.

43. Jia Y, Zhang X, Yu J, et al (2017). Acupuncture for patients with mild to moderate Alzheimer's disease: a randomized controlled trial. BMC Complement Altern Med, 17(1):556.

44. Cheng H, Zhao D (2017). The Clinical Observation of Senile Dementia Treated with Bushen Huoxue Decoction in Combination with Acupuncture. Henan Traditional Chinese Medicine, 37 (04):619-621.

45. Li T, Wan G, Zhang Y (2014). Clinical observation of "BuShenYiNaoTang" acupuncture combined with rehabilitation training in the treatment of senile dementia. Human Journal of Traditional Chinese Medicine, 30 (08):104-106.

46. Tang S, Liu S, Zeng P, et al (2014). Clinical Observation of "BuShenYiNaoTang" Combined with Acupuncture in the Treatment of Alzheimer's Disease. Jiangsí Journal of Traditional Chinese Medicine, 45 (08):47-49.

47. Wang Z, Wang Z (2017). Study on Dihuang Yizhi prescription , electroacupuncture combined with Donepezil Hydrochloride Tablets in the treatment of Alzheimer's dementia. Modern Journal of Integrated Traditional Chinese and Western Medicine, 26 (30):3331-3333+3337.

48. Yao A, Wang X, Dong L, et al (2016). Observation on the Effect of the Treatment

Available at:  http://ijph.tums.ac.ir
of Alzheimer's Diseases with Rehmannia Decoction Combined Acupuncture at Baihui Point. *World Journal of Integrated Traditional and Western Medicine*, 11 (05):667-670.

49. Wang K, Zhang L, Chen X (2015). Clinical observation on 36 cases of Alzheimer's disease treated by electro-acupuncture Dazhui (GV 14) and Baihui (GV 20). *China Journal of Traditional Chinese Medicine and Pharmacy*, 30 (03):784-786.

50. Yang X, Lin D (2015). Clinical study of electroacupuncture combined with "DiHuangYinZi" in Treating Patients with Alzheimer's Disease. *Journal of Clinical Acupuncture and Moxibustion*, 31 (09):8-10.

51. Liu J (2018). Observation on the efficacy of "JinSanZhen" combined with donepezil hydrochloride and nimodipine in the treatment of dementia. *Modern Journal of Integrated Traditional Chinese and Western Medicine*, 27 (32):3587-3590.

52. Jia Y, Meng D, Sun M, et al (2017). Clinical Observation of Sanjiao Acupuncture on Mild to Moderate Alzheimer's Disease: A Randomized Controlled Trial. *Liaoning Journal of Traditional Chinese Medicine*, 44 (09):1911-1914.

53. Lin C, Zhang J, Guo J, et al (2014). Effect of "TiaoShenYiZhi" acupuncture in the treatment of mild Alzheimer's disease. *Chinese Journal of Gerontology*, 34(08):2225-2226.

54. Zhao L, Ma L, Li Y, et al (2007). Observation on the Effect of acupuncture on the treatment of senile dementia. *Journal of Clinical Acupuncture and Moxibustion*, (09):42-43.

55. Dai J, Xiao J, Li S, et al (2019). Effect of Acupuncture Combined with Rehabilitation Training on Rehabilitation of Patients with Senile Dementia. *Clinical Journal of Traditional Chinese Medicine*, 31 (02):317-319.

56. Liu G, Yuan L (2005). Clinical observation on acupuncture combined with music for treatment of Alzheimer disease. *Zhongguo Zhen Jiu*, 25(6):390-392.

57. Zhou Y, Jia J (2008). Clinical observation on catgut implantation at acupoint for treatment of Alzheimer's disease. *Zhongguo Zhen Jiu*, 28(1):37-40.

58. Sun H, Zhu M, Zhang W (2018). Effects of Serum Acetyl Choline and Amyloid-Beta Protein by Using Acupuncture Baihui (GV20) and Yongquan (KI1) Acupoint to Treat Patients with Alzheimer Disease. *World Chinese Medicine*, 13 (11):213-215+219.

59. Chen D, Zheng Y, Chen M (2018). Therapeutic Effects of Acupuncture on Senile Dementia and Its Influence on Cytokine and Blood Lipid Metabolism. *World Chinese Medicine (Chinese)*, 13 (03):719-721+726.

60. Bi D, Liu Q, Chen Y, et al (2016). Therapeutic observation on electroacupuncture at Zusanli (ST 36) and Fenglong (ST 40) for senile dementia. *Journal of Acupuncture and Tuina Science*, 14 (06):386-390.

61. Wang Y, Qin W, Yu C (2014). Clinical observation on effect of cranial suture acupuncture combined with donepezil hydrochloride tablets for Alzheimer's disease. *World Journal of Acupuncture-Moxibustion*, 24 (02):19-24.

62. Yuxiao Z, Golison, Lili Z, et al (2020). Effects of Acupoint Combined with Music Therapy on Cognitive Function and Activities of Daily Living in Patients with Mild and Moderate Alzheimer's Disease. *World Chinese Medicine*, 15 (13):1998-2001.

63. Xia K, Wang Y, Zhang M, et al (2020). Effect of Electroacupuncture at Baihui (GV20) and Fengfu (GV16) on the Learning and Memory Abilities in Alzheimer’s Disease Patients. *Shanghai Journal of Acupuncture and Moxibustion*, 39(08):974-978.

64. Wang Y, Wang Y, Zhou X, et al (2020). Clinical observation of needing Qin's eight head acupoints combined with western medicine in the treatment of Alzheimer's disease. *Shanghai Journal of Traditional Chinese Medicine*, 54 (S1):69-73.

65. Shoji M (2010). Drug therapy for Alzheimer's disease. *Brain and nerve= Shinkei kenkyu no shinsyo*, 62 (7):777-785.

66. Wu J, Wang Y, Zhang Z, et al (2015). Herbal medicine in the treatment of Alzheimer's disease. *Chinese Journal of Integrative Medicine*, 21 (2):102-107.

67. Zhu J, Arsovsk B, Kozovska K (2019). Alzheimer's disease treatment with Traditional Chinese Medicine. *International Journal of Research-Granthisaaday*, 7 (10):448-451.

68. Huang Q, Luo D, Chen L, et al (2019). Effectiveness of Acupuncture for Alzheimer’s...
Disease: An Updated Systematic Review and Meta-analysis. *Curr Med Sci*, 39 (3):500-511.
69. Lai X, Wen H, Li Y, et al (2020). The Comparative Efficacy of Multiple Interventions for Mild Cognitive Impairment in Alzheimer's Disease: A Bayesian Network Meta-Analysis. *Front Aging Neurol*, 12:121.
70. Leisring MA (2008). The AβCs of Aβ-cleaving proteases. *J Biol Chem*, 283 (44):29645-29649.
71. Scheltens P, Blennow K, Breteler MM, et al (2016). Alzheimer's disease. *Lancet*, 388 (10043):505-517.
72. Mehta PD (2007). Amyloid beta protein as a marker or risk factor of Alzheimer's disease. *Curr Alzheimer Res*, 4(4):359-363.
73. Grundke-Iqbal I, Iqbal K, Quinlan M, et al (1986). Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. *J Biol Chem*, 261 (13):6084-6089.
74. Ittner LM, Götz J (2011). Amyloid-β and tau—a toxic pas de deux in Alzheimer's disease. *Nat Rev Neurosci*, 12(2):65-72.
75. Mattsson N, Zetterberg H, Janelidze S, et al (2016). Plasma tau in Alzheimer disease. *Neurology*, 87(17):1827-1835.
76. Luo D, Zou T, Huang Q (2006). Clinical observation on electroacupuncture on senile dementia and the effect of beta-amyloid protein expression. *Medicine World*, (9):64-66.
77. Jiang X, Jiang G, Yu Y (2008). Effects of acupuncture on tau protein expression in brain tissue of senile dementia rats. *Journal of Clinical Acupuncture and Moxibustion*, 24 (11):38-39.
78. Tang Y, Yu S, Liu X, et al (2005). Effect on the signal pathway of hippocampal protein kinase in senile dementia rats with the activation of electroacupuncture. *Chinese Journal of Clinical Rehabilitation*, 9(1):124-125.
79. Liu Z, Liu J, Qu H (2009). Experimental study on effect of Ele-acupuncture on cognitive impairment of Alzheimer's disease model rats. *China Journal of Traditional Chinese Medicine and Pharmacy*, 24 (6):791-793.
80. He F, Yang J, Shi H, et al (2004). Effect of electroacupuncture at related acupoint of jing on the function of learning and memory and the ability of eliminating free radicals in rats with vascular dementia. *Chinese Journal of Clinical Rehabilitation*, 8(10):1902-1903.
81. Yu S, Lao S, Han T, et al (2006). Effect of electroacupuncture therapy on morphological synaptic plasticity in hippocampal neurons of rats with senile dementia. *Chinese Journal of Neuromedicine*, 5(4):369-371.
82. Lu S, Shao X, Tang Y, et al (2008). Effects of electroacupuncture on neural cell adhesion of synaptic plasticity in the hippocampus of SAMP8. *Chinese Journal of Rehabilitation Medicine*, 23(12):1057-1060.
83. Wang W, Tang W, Sun Z (2011). Effect of Electroacupuncture on Learning and Memory Function and Synaptic Expression in CA1 Area of Hippocampus in Rats with Alzheimer's Disease. *Chinese Journal of Traditional Medical Science and Technology*, 18 (1):1-2.
84. Yu CC, Ma CY, Wang H, et al (2019). Effects of Acupuncture on Alzheimer's Disease: Evidence from Neuroimaging Studies. *Chin J Integr Med*, 25(8):631-640.